News

Despite MRAs, not all types of inspections are recognised in practice; for example, "for-cause" inspections have so far not, or only rarely, been covered. These are also increasingly conducted without prior notice.

More

At the end of March 2026, the IPEC announced the updated Version 3 of its 'Excipient Stability Guide for Pharmaceutical Excipients' in a notice on its website. This was first published in 2010 and is currently only available and viewable in the IPEC members' area. Following a three-month period (expected to end on 30 June 2026), the updated guide is to be published in full.

More

The FDA recently issued a Warning Letter to a manufacturer in Houston that raises the question of whether any aspect of the operation complied with Good Manufacturing Practice at all. Processes, facilities, equipment, controls, and validation - the list of deficiencies is extensive.

More

In April 2026, the IPEC announced the updated Version 3 of the ‘Qualification of Excipients for Use in Pharmaceuticals: Guide & Checklist’ on its website. This guide was first published in 2008 and is currently only available in the IPEC members’ area.

More

The European Medicines Agency (EMA) has published on its website the 3-year work plan (2026–2028) of the GMDP Inspectors Working Group (GMDP IWG) as well as the 2025 annual report. In addition to numerous GMP-related topics, both documents also highlight important aspects that are relevant to the GDP area.

More

In April 2026, the updated texts of Ph. Eur. 13.1 were published and listed on the EDQM website under the Ph. Eur. section. These include, for example, the revised general chapter '2.1.7. Balances for analytical purposes'.

More

Following the revision of the ICH Q9 guideline 'Quality Risk Management 2023', the accompanying training material was also published. This has now been updated with regard to the two annexes. Annex I describes quality risk methods and tools, and Annex II describes possible applications of quality risk management (QRM).

More

During the inspection of a US site belonging to a French pharmaceutical manufacturer, the FDA identified serious deficiencies, including in a process system for the manufacture of OTC drugs. The deficiencies relate to both the equipment design and its qualification. Read more here.

More

A warning letter from the FDA highlights the importance of microbiological and analytical testing of medicinal products. For example, it criticises inadequate testing of culture media with GPT and a lack of BCC testing.

More

The U.S. Food and Drug Administration (FDA) has published a new Warning Letter that refers back to an inspection at a Chinese drug manufacturing facility. At the center of the letter is an analytical compliance failure frequently cited in Warning Letters: release decisions without appropriate laboratory evidence.

More
x
Search